Literature DB >> 18023335

Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.

Jan Lötvall1, Jaro Ankerst.   

Abstract

RATIONALE: Formoterol is approved as asthma rescue medication in many countries. The exact duration of the airway vs. systemic effects of formoterol compared with another rescue medication, salbutamol, has not been evaluated.
OBJECTIVE: To assess the duration of airway bronchodilatory effects vs. systemic effects of inhaled formoterol and salbutamol in asthmatic patients.
METHODS: Twenty-six patients with stable and reversible asthma were given single doses of formoterol dry-powder inhaler (OxisTurbuhaler) 2x9 microg (lower dose; LD) and 6x9 microg (higher dose; HD), salbutamol (VentolinDiskhaler) 3x400 microg (LD) and 9x400 microg (HD), and placebo in a randomized, double-blind, crossover trial. Airway and systemic effects were assessed by forced expiratory volume in 1s (FEV1), serum potassium, blood pressure, corrected QT-interval (QTc), and palpitation and tremor scores. Time with clinically relevant bronchodilation (FEV1 increase 12%) without clinically relevant markers of systemic effects (serum potassium suppression 0.2 mmol/L, QTc-prolongation 20 ms, or heart rate increase 8 beats per minute) was evaluated.
RESULTS: Bronchodilation was maintained for 24h with both formoterol doses and for 7-11h with salbutamol. Maximum bronchodilation and systemic effects were similar after formoterol and salbutamol, except for statistically significantly larger maximum heart rate and palpitation and tremor scores after salbutamol. Systemic responses were similarly brief for formoterol and salbutamol (7 h).
CONCLUSIONS: The airway effects of inhaled formoterol are of long duration, whereas the systemic effects are of a similarly short duration as salbutamol. Thus, the time with clinically relevant bronchodilation without systemic effects is substantially longer after formoterol than after salbutamol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023335     DOI: 10.1016/j.rmed.2007.10.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  Tremor severity and age: a cross-sectional, population-based study of 2,524 young and midlife normal adults.

Authors:  Elan D Louis; Danella Hafeman; Faruque Parvez; Xinhua Liu; Roy N Alcalay; Tariqul Islam; Alauddin Ahmed; Abu Bakar Siddique; Tazul Islam Patwary; Stephanie Melkonian; Maria Argos; Diane Levy; Habibul Ahsan
Journal:  Mov Disord       Date:  2011-03-25       Impact factor: 10.338

Review 2.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 3.  Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma.

Authors:  Emma J Welsh; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

4.  Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial.

Authors:  Robert A Nathan; Anthony D'Urzo; Viktor Blazhko; Kirsten Kaiser
Journal:  BMC Pulm Med       Date:  2012-10-18       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.